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The benefit of guideline-determined medical therapy (GDMT) and devices on (A) all-cause mortality and (B) on heart failure and sudden death (2,7-10). The PARADIGM-HF trial was versus angiotensin-converting enzyme inhibitor (ACEI). The observed ARNI benefits were adjusted for ACEI benefit to provide an estimate of angiotensin receptor-neprilysin inhibitor (ARNI) versus placebo (9, 10) . ARB ¼ angiotensin receptor blocker; BB ¼ beta-blocker; CRT-D ¼ cardiac resynchronization therapy defibrillator; CRT-P ¼ cardiac resynchronization therapy pacemaker; ICD ¼ implantable-cardioverter defibrillator; MRA ¼ mineralcorticoid receptor antagonist.
Nonischemics CRT-P Versus CRT-D A P R I L 4 , 2 0 1 7 : 1 6 7 9 -8 2 sodium/creatinine, and systolic blood pressure closer to 140 mm Hg have a higher proportion of sudden death (14) . Ischemic etiology did not enter the multivariate model, but post hoc testing suggested that the predicted proportion of sudden death would increase by w3% for ICM versus NICM (i.e., 47% to 50%). Observational ICD trials, in which patients whose primary mode of death was sudden (>50% of all deaths), derived a much greater benefit from an ICD than those with <50% sudden death (15) . We suspect the opposite is true with CRT-Ps. In Table 1 in the paper by Barra et al., the NICM patients who received CRT-Ps versus CRT-Ds were 9 years older, 28% more were women, and 8% more had QRS intervals $150 ms; these groups had a greater benefit from CRT-Ps, and conversely, less benefit from the addition of an ICD. There was less chronic kidney disease (CKD) in the CRT-P group.
These differences between the CRT-P and CRT-D groups were similar in both the ICM and NICM cohorts. Because of the lack of ICD benefit for patients older than 68 years of age in the DANISH trial, and diminished benefit with advancing age for ICDs (16), it should not be surprising that a largely older patient population with CRT-Ps that had a low rate of sudden death (0.4%/year) did not benefit from the addition of an ICD (17) . However, these results
should not be applied to the larger group of younger patients who received CRT-Ds in clinical trials and in this registry (2,6).
ICDs (CRT-Ds vs. CRT-Ps) provide the greatest benefit in patients with the following:
High proportion of sudden death (>35%) (15, 18) ; Sudden death rate $1.2%/year ($6% over 5 years) (17) ; and Annual mortality of #25% (3-year mean survival) (7, (18) (19) (20) .
Patients who do not meet these criteria will not derive a meaningful benefit from an ICD.
This observational cohort does raise the issue of Sudden death is w40% of the total mortality and increases directly proportional to the total mortality. In cardiac resynchronization therapy (CRT)-eligible patients who did not receive CRT, the proportion of sudden death was much lower, in the 25% range (2,7).
HF ¼ heart failure. Adapted from Carson et al. (7) and Desai et al. (10) .
